BerandaALMKT • EPA
add
Mauna Kea Technologies SA
Tutup sebelumnya
€0,12
Rentang hari
€0,11 - €0,13
Rentang tahun
€0,061 - €0,20
Kapitalisasi pasar
21,40 jt EUR
Volume Rata-Rata
1,29 jt
Rasio P/E
-
Hasil dividen
-
Bursa utama
EPA
Dalam berita
Keuangan
Laporan Laba Rugi
Pendapatan
Penghasilan bersih
| (EUR) | Jun 2025info | Perubahan Y/Y |
|---|---|---|
Pendapatan | 2,02 jt | -5,58% |
Biaya operasional | 3,02 jt | -13,98% |
Penghasilan bersih | -2,33 jt | 0,36% |
Margin laba bersih | -115,83 | -5,52% |
Penghasilan per saham | — | — |
EBITDA | -1,35 jt | 12,08% |
Tarif pajak efektif | -1,21% | — |
Neraca
Total aset
Total liabilitas
| (EUR) | Jun 2025info | Perubahan Y/Y |
|---|---|---|
Investasi tunai jangka pdk | 663,00 rb | -82,63% |
Total aset | 12,66 jt | -30,23% |
Total liabilitas | 42,08 jt | 9,33% |
Total ekuitas | -29,42 jt | — |
Saham yang beredar | 79,74 jt | — |
Harga terhadap nilai buku | -0,31 | — |
Tingkat pengembalian aset | -27,57% | — |
Tingkat pengembalian modal | -101,28% | — |
Arus Kas
Perubahan kas bersih
| (EUR) | Jun 2025info | Perubahan Y/Y |
|---|---|---|
Penghasilan bersih | -2,33 jt | 0,36% |
Kas dari operasi | -1,10 jt | 41,90% |
Kas dari investasi | 116,00 rb | 217,81% |
Kas dari pembiayaan | 336,50 rb | 248,57% |
Perubahan kas bersih | -677,00 rb | 67,54% |
Arus kas bebas | -460,56 rb | 43,00% |
Tentang
Mauna Kea Technologies is a global medical device company focused on endomicroscopy, the field of microscopic imaging during endoscopy procedures. The company researches, develops and markets tools to visualize, detect, and rule out abnormalities including malignant and pre-malignant tumors or lesions in the gastrointestinal and pulmonary tracts.
The company makes Cellvizio, a probe-based Confocal Laser Endomicroscopy system, which provides physicians and researchers with real-time access to histological information during standard endoscopy procedures through high-resolution cellular imaging of internal tissues.
Cellvizio is used in medical applications such as gastrointestinal endoscopy, pulmonology and urology to help physicians diagnose lesions and make accurate treatment decisions in real-time.
Cellvizio went public in July 2011 and trades on the Euronext Paris exchange. Wikipedia
Didirikan
2000
Situs
Karyawan
61